Nothgedrungene Rechtsbefugte Vorstellung, Beschwehrung und diverses unterthäniges Bitten unser Derer provisionaliter verordneten dreyen Casten-Meistern Contra Beer Löw Isaac und Süßkind Samuel Stern : Ad Decreta de 29. Octobr. 1751 & 7. Jan. und 1. Martii 1752 ; Cum Postscripto

[Jacob Ochs ; Beer Hertz Oppenheimer ; Moyses Benedickt Beyfuß] [[Elektronische Ressource]]

Guarantie-Schein von acht gesessenen Bürgerlichen Deputirten, die Einkünffte der Stadt auff hundert tausend Gülden jährlichen Einkünfften, auff den Fuß, wie sie Magistratus bißher erhebt, gleich in primo anno weiter und hernach viel höher zuverrechnen : In Causa Commissionis Impetrantischer Bürgerschafft der Kayserl. Freyen Reichs- auch Wahl- und Crönungs-Stadt Franckfurth Contra E. E. Rath allda ; Ihro Röm. Kayserl. Majestät benebenst einem allerunterthänigsten Memorial sub lit. B originaliter ... den 28. Jan. 1715 ... überreicht

[David Düring, Peter Bischoff, Johannes Klotz, Johann Conrad Siegling, Paul Hennrici, David Klotz, Joh. Dietrich Notebohm, Joachim Hoppe] [[Elektronische Ressource]]

Die In zehen Jahren zum zweitenmal mit Feuer heimgesuchte Juden-Gaß : da nemlich 1711 den 14. Jan. des Abends um 8 Uhr, biß den andern Tag des Abends, die gantze biß auf den kleinsten Splitter, zu einem Aschen-Hauffen wurde ; In diesem 1721sten Jahr ... entstund abermal eine entsetzliche Feuers-Brunst ...

[I. B. G. ?] [[Elektronische Ressource]]

Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data

BACKGROUND The best-known cause of intolerance to fluoropyrimidines is dihydropyrimidine dehydrogenase (DPD) deficiency, which can result from deleterious polymorphisms in the gene encoding DPD (DPYD), including DPYD*2A and c.2846A>T. Three other variants-DPYD c.1679T>G, c.1236G>A/HapB3, and c.1601G>A-have been associated with DPD deficiency, but no definitive evidence for the clinical validity of these variants is available. The primary objective of this systematic review and meta-analysis was to assess the clinical validity of c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity. METHODS We did a systematic review of the literature published before Dec 17, 2014, to identify cohort studies investigating associations between DPYD c.1679T>G, c.1236G>A/HapB3, and c.1601G>A and severe (grade ≥3) fluoropyrimidine-associated toxicity in patients treated with fluoropyrimidines (fluorouracil, capecitabine, or tegafur-uracil as single agents, in combination with other anticancer drugs, or with radiotherapy). Individual patient data were retrieved and analysed in a multivariable analysis to obtain an adjusted relative risk (RR). Effect estimates were pooled by use of a random-effects meta-analysis. The threshold for significance was set at a p value of less than 0·0167 (Bonferroni correction). FINDINGS 7365 patients from eight studies were included in the meta-analysis. DPYD c.1679T>G was significantly associated with fluoropyrimidine-associated toxicity (adjusted RR 4·40, 95% CI 2·08-9·30, p<0·0001), as was c.1236G>A/HapB3 (1·59, 1·29-1·97, p<0·0001). The association between c.1601G>A and fluoropyrimidine-associated toxicity was not significant (adjusted RR 1·52, 95% CI 0·86-2·70, p=0·15). Analysis of individual types of toxicity showed consistent associations of c.1679T>G and c.1236G>A/HapB3 with gastrointestinal toxicity (adjusted RR 5·72, 95% CI 1·40-23·33, p=0·015; and 2·04, 1·49-2·78, p<0·0001, respectively) and haematological toxicity (adjusted RR 9·76, 95% CI 3·03-31·48, p=0·00014; and 2·07, 1·17-3·68, p=0·013, respectively), but not with hand-foot syndrome. DPYD*2A and c.2846A>T were also significantly associated with severe fluoropyrimidine-associated toxicity (adjusted RR 2·85, 95% CI 1·75-4·62, p<0·0001; and 3·02, 2·22-4·10, p<0·0001, respectively). INTERPRETATION DPYD variants c.1679T>G and c.1236G>A/HapB3 are clinically relevant predictors of fluoropyrimidine-associated toxicity. Upfront screening for these variants, in addition to the established variants DPYD*2A and c.2846A>T, is recommended to improve the safety of patients with cancer treated with fluoropyrimidines. FUNDING None.

Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial.

BACKGROUND REG1 is a novel anticoagulation system consisting of pegnivacogin, an RNA aptamer inhibitor of coagulation factor IXa, and anivamersen, a complementary sequence reversal oligonucleotide. We tested the hypothesis that near complete inhibition of factor IXa with pegnivacogin during percutaneous coronary intervention, followed by partial reversal with anivamersen, would reduce ischaemic events compared with bivalirudin, without increasing bleeding. METHODS We did a randomised, open-label, active-controlled, multicentre, superiority trial to compare REG1 with bivalirudin at 225 hospitals in North America and Europe. We planned to randomly allocate 13,200 patients undergoing percutaneous coronary intervention in a 1:1 ratio to either REG1 (pegnivacogin 1 mg/kg bolus [>99% factor IXa inhibition] followed by 80% reversal with anivamersen after percutaneous coronary intervention) or bivalirudin. Exclusion criteria included ST segment elevation myocardial infarction within 48 h. The primary efficacy endpoint was the composite of all-cause death, myocardial infarction, stroke, and unplanned target lesion revascularisation by day 3 after randomisation. The principal safety endpoint was major bleeding. Analysis was by intention to treat. This trial is registered at ClinicalTrials.gov, identifier NCT01848106. The trial was terminated early after enrolment of 3232 patients due to severe allergic reactions. FINDINGS 1616 patients were allocated REG1 and 1616 were assigned bivalirudin, of whom 1605 and 1601 patients, respectively, received the assigned treatment. Severe allergic reactions were reported in ten (1%) of 1605 patients receiving REG1 versus one (<1%) of 1601 patients treated with bivalirudin. The composite primary endpoint did not differ between groups, with 108 (7%) of 1616 patients assigned REG1 and 103 (6%) of 1616 allocated bivalirudin reporting a primary endpoint event (odds ratio [OR] 1·05, 95% CI 0·80-1·39; p=0·72). Major bleeding was similar between treatment groups (seven [<1%] of 1605 receiving REG1 vs two [<1%] of 1601 treated with bivalirudin; OR 3·49, 95% CI 0·73-16·82; p=0·10), but major or minor bleeding was increased with REG1 (104 [6%] vs 65 [4%]; 1·64, 1·19-2·25; p=0·002). INTERPRETATION The reversible factor IXa inhibitor REG1, as currently formulated, is associated with severe allergic reactions. Although statistical power was limited because of early termination, there was no evidence that REG1 reduced ischaemic events or bleeding compared with bivalirudin. FUNDING Regado Biosciences Inc.

Kurtzer Bericht von dem Cometen und dessen Lauff : Welcher gestalt derselbe den 4, 14. Decembris des vorigen 1664. Jahrs in Rom gesehen, und daselbst von gemeltem Dato an, biß auf den 20, 20 desselben Monats observiret werden können ; Gegeben zu Rom 3. Jan. 1665

Athanasius Kircherus

Erschröckliches Feuer- und Wunder-Zeichen : Mit grausamen Canoniren und Schiessen, welches den 16. Jan. dieses 1697sten Jahres ... an den Himmel über der Stadt Metz gehöret und gesehen worden, wie zusehen ist

Original sehr knapp beschnitten, Plattenrand nicht erkennbar

Der Hottentotten-Aufstand : Studie über die Vorgänge im Namalande von Jan. 1904 bis zum Jan. 1905 u. d. Aussichten d. Niederwerfung d. Aufstandes

von v. François

Ms. Ff. Mus. 1474 - Feria 1. Pentecostes : [wer mich liebet, der wird mein Wort halten]

Telemann. [Text von Gottfried Simonis]

Jan de Graan, Brustbild

Signatur des Originals: S 36/F00598